Cancer patients are at an increased risk of developing venous thromboembolism (VTE), which includes conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This heightened risk is due to several factors, including the cancer itself, chemotherapy, and immobility. Consequently, Warfarin is often prescribed to cancer patients to manage and prevent these potentially life-threatening clots.
